ArticleTranslational lung cancer research2026

First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study.

Kuofang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.